Business
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third-quarter of 2025.
About this update from Eli Lilly And Company
[{"type":"list","items":[{"val":[{"type":"text","content":"Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound.","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Q3 2025 EPS increased by $5.14 to $6.21 on a reported basis and increased by $5.84 to $7.02 on a non-GAAP basis. ","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70. ","length":240,"tagName":"p"}]},{"val":[{"type":"text","content":"Pipeline progress included positive results in four Phase 3 trials of orforglipron, across type 2 diabetes and obesity, with plans to submit to global regulatory authorities by the end of the year for the treatment of obesity. ","length":226,"tagName":"p"}]},{"val":[{"type":"text","content":"Regulatory progress included U.S. FDA approval of Inluriyo (imlunestrant) for certain adults with advanced or metastatic breast cancer.","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"Manufacturing progress included announcements of two new facilities in Virginia and Texas, and the expansion of Lilly's existing Puerto Rico site.","length":150,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":966,"olType":false},{"type":"text","content":"INDIANAPOLIS, Oct. 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third-quarter of 2025.","length":146,"tagName":"p"},{"type":"text","content":""Lilly delivered another strong quarter, with 54% revenue growth year-over-year driven by continued demand for our incretin portfolio," said David A. Ricks, Lilly chair and CEO. "We advanced orforglipron through four additional Phase 3 trials, enabling global obesity submissions by year-end, and we achieved U.S. FDA approval of Inluriyo (imlunestrant)—marking key progress across our pipeline. We continue to increase manufacturing capacity, announcing new facilities in Virginia and Texas and an expansion of our site in Puerto Rico."","length":557,"tagName":"p"},{"type":"text","content":"Financial Results","length":17,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"cols...